Lv0
0 积分 2024-12-26 加入
Recent Trends in the Management of Hepatocellular Carcinoma with Special Emphasis on Treatment with Regorafenib and Immune Checkpoint Inhibitors
11小时前
已完结
Letter Regarding ‘Multimode Ultrasound Model for Predicting the Early Treatment Response of Anti-VEGF Agents Plus Anti-PD-1 Antibody in Patients with Unresectable Hepatocellular Carcinoma’
11小时前
已完结
Letter Regarding ‘Multimode Ultrasound Model for Predicting the Early Treatment Response of Anti-VEGF Agents Plus Anti-PD-1 Antibody in Patients with Unresectable Hepatocellular Carcinoma’
11小时前
已关闭
iRGD-mediated liposomal nanoplatforms for improving hepatocellular carcinoma targeted combination immunotherapy and monitoring tumor response via IVIM-MRI
11小时前
已完结
MRI-based Nomogram Predicts the Risk of Progression of Unresectable Hepatocellular Carcinoma After Combined Lenvatinib and anti-PD-1 Antibody Therapy
11小时前
已完结
A case of hepatocellular carcinoma with "pseudoprogression" followed by complete response to atezolizumab plus bevacizumab
12小时前
已完结
The cost-effectiveness of new first-line therapies approved in advanced hepatocellular carcinoma
12小时前
已完结
Characterization of response to atezolizumab + bevacizumab versus sorafenib for hepatocellular carcinoma: Results from the IMbrave150 trial
12小时前
已完结
Radiological response to nivolumab in patients with hepatocellular carcinoma: A multicenter analysis of real-life practice
12小时前
已完结
Impact of radiological response and pattern of progression in patients with HCC treated by atezolizumab-bevacizumab
12小时前
已完结
皖公网安备34019202002308
